Brainstorm's clinical trials featured on the israeli radio popular morning news (yoman haboker)

New york & petach tikvah, israel--(business wire)--brainstorm cell therapeutics inc. (otcbb: bcli), a developer of innovative adult stem cell technologies for debilitating neurodegenerative disorders, today announced that brainstorm’s phase i/ii clinical trial for amyotrophic lateral sclerosis (als) at the hadassah medical center, was featured on the israeli radio popular morning news (yoman haboker). brainstorm’s nurown™ autologous adult stem cell therapy is in clinical trial for als, often referred to as lou gehrig's disease, a devastating neurodegenerative disease. we attach the link for our hebrew speaking shareholders who can read the news and listen to the broadcast. http://www.iba.org.il/bet/bet.aspx?type=286&entity=799204 the interview with brainstorm’s ceo, dr. adrian harel, outlines the company’s current activities and describes its plans for future developments. safe harbor statementstatements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause brainstorm cell therapeutics inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. the potential risks and uncertainties include risks associated with brainstorm's limited operating history, history of losses; minimal working capital, dependence on its license to ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in brainstorm's annual report on form 10-k and quarterly reports on form 10-q available at http://www.sec.gov. the company does not undertake any obligation to update forward-looking statements made by us.
BCLI Ratings Summary
BCLI Quant Ranking